Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Average Target Price of $110.91

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have earned an average recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $110.91.

GPCR has been the subject of several recent research reports. Weiss Ratings upgraded Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GPCR. Sterling Capital Management LLC boosted its stake in Structure Therapeutics by 63.6% during the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock valued at $105,000 after purchasing an additional 1,300 shares during the last quarter. IFP Advisors Inc bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $46,000. Squarepoint Ops LLC increased its holdings in Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock worth $6,740,000 after purchasing an additional 102,929 shares in the last quarter. Seven Fleet Capital Management LP increased its holdings in Structure Therapeutics by 197.8% during the 2nd quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock worth $1,442,000 after purchasing an additional 17,800 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after purchasing an additional 119,146 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $21.19 on Wednesday. The stock has a 50-day moving average of $36.46 and a 200-day moving average of $43.02. Structure Therapeutics has a one year low of $20.73 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts forecast that Structure Therapeutics will post -1.87 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.